Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dainippon Sumitomo reports novel antidiabetic agents in recent patent

May 14, 2007

Phase I trials begin for Oramed Insulin capsules

May 11, 2007

Adverse event reported in phase II anemia trial of FG-2216

May 10, 2007

AEterna Zentaris regains rights for cetrorelix from Solvay

May 10, 2007

European CHMP recommends approval of Siklos

May 10, 2007

Recent patents disclose new agents for metabolic disorders

May 10, 2007

Pergoveris recommended for E.U. approval

May 9, 2007

Enjuvia receives two new FDA approvals

May 9, 2007

Aastrom cleared for phase III study of bone repair cell product in osteonecrosis

May 9, 2007

Enrollment open in phase I study of new obesity candidate trodusquemine

May 9, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...